Ascletis Pharma Develops Once-Daily Oral Combination for Obesity and Metabolic Diseases

Ascletis Pharma Inc. has announced the development of a new fixed-dose combination (FDC) tablet, designated as ASC30_39, targeting metabolic diseases and obesity. The treatment combines a GLP-1 receptor agonist with an amylin receptor agonist in a single oral dose designed for once-daily administration. Recent preclinical studies conducted on animal models demonstrated that the combination maintains comparable pharmacokinetics to its individual components, featuring a half-life of approximately 12 hours. This strategic move aims to enhance the efficacy of weight loss treatments by leveraging dual-receptor targeting in a convenient oral format. While the progress is a positive step into the high-growth obesity drug market, the project remains in the early clinical stages, suggesting a moderate immediate impact. Investors are closely monitoring the development as the company seeks to compete in the rapidly expanding metabolic health sector.